The FDA has accepted for review the resubmitted BLA for prademagene zamikeracel for recessive dystrophic epidermolysis bullosa.

StockNews.com lowered shares of Abeona Therapeutics (NASDAQ:ABEO – Free Report) from a hold rating to a sell rating in a report released on Tuesday morning. Several other equities analysts also ...

The San Diego biotech made an unsolicited bid to buy Evotec for 2 billion euros. Elsewhere, Bluebird recorded its first ...